Clinical trial

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

NCT04504669

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-08-18

PhasePHASE1

Study timeline

Study start (actual)2020-08-18Date precision: day

Registry last updated2024-11-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Clear Cell Renal Cell Cancerunresolved

Non-Small-Cell Lung Cancerunresolved

Triple Negative Breast Neoplasmsunresolved

Squamous Cell Cancer of Head and Neckunresolved

Small Cell Lung Cancerunresolved

Gastroesophageal Cancerunresolved

Melanomaunresolved

Cervical Cancerunresolved

Advanced Solid Tumoursunresolved

Interventions

DurvalumabBIOLOGICAL

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

MadridSpain2 HoustonTexas, United States1 BaltimoreMaryland, United States1 St LouisMissouri, United States1 TorontoOntario, Canada1 BarcelonaSpain1 MadisonWisconsin, United States1 RennesFrance1 VillejuifFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04504669 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.